A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

Tel Aviv University scientists say that they can inject CRISPR genetic 'molecular scissors' to shrink tumors by 90%; ...

The competition between U.S. and Chinese biotech companies is particularly fierce in one field: CRISPR gene editing. Here are ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

Bioengineering professor and The Grainger College of Engineering's Dean, Rashid Bashir, led a team of researchers in a ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on wallstreetbets Subreddit Page by MADD-Scientis. In this ...

Researchers from Tel Aviv University utilized CRISPR to cut a single gene from cancer cells of head and neck tumors—and ...

CRISPR libraries enable scientists to systematically investigate gene functions, identify novel drug targets, and develop personalized therapies.

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.